Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.
Description: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 2 week mortality Time: 2 weeks after admission at ICUDescription: the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU
Measure: incidence of venous thromboembolism Time: during ICU stay up till 3th of May 2020Description: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 1 week mortality Time: 1 week after admission at ICUDescription: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 3 week mortality Time: 3 weeks after admission at ICUDescription: mortality was assessed in all COVID 19 patients admitted to the ICU
Measure: 1 month mortality Time: 1 month after admission at ICUDescription: incidence of acute kidney failure in all COVID 19 patients admitted to the ICU
Measure: incidence of kidney failure Time: during ICU stay up till 3th of May 2020Description: incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU
Measure: incidence of continuous renal replacement therapy (CRRT) Time: during ICU stay up till 3th of May 2020Description: evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU
Measure: lowest PaO2/FiO2 (P/F) ratio Time: during ICU stay up till 3th of May 2020Description: evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU
Measure: highest Sequential Organ Failure Assessment (SOFA) score Time: during ICU stay up till 3th of May 2020Description: evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU
Measure: length of stay Time: during ICU and hospital stay up till 3th of May 2020Description: evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU
Measure: highest bilirubin Time: during ICU stay up till 3th of May 2020Description: evaluation of the highest AST level in all COVID 19 patients admitted to the ICU
Measure: highest ( AST Time: during ICU stay up till 3th of May 2020Description: evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU
Measure: highest Aspartaat-Amino-Transferase (ALT) Time: during ICU stay up till 3th of May 2020Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports